NGS Sample Preparation Market Size, Share, Opportunities, And Trends By Product (Reagent And Consumables, Workstations), By Application (Diagnostics, Drug Discovery, Others), By End-user (Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Academic & Research Institutes, Others), And By Geography - Forecasts From 2024 To 2029

  • Published : Mar 2024
  • Report Code : KSI061616801
  • Pages : 140

The NGS sample preparation market is anticipated to grow significantly over the forecast period.

The market for NGS (Next Generation Sequencing) sample preparation is expected to grow due to developments in personalized medicine and genomic research. A crucial phase in NGS workflows is sample preparation, which includes target enrichment, library preparation, and DNA fragmentation. Leading companies in the industry are creating cutting-edge approaches to automate and simplify these procedures, increasing productivity and cutting expenses. The market is being driven by the growing need for NGS across a range of applications, including agricultural genomics, infectious diseases, and oncology.

Further driving market expansion are pharmaceutical and biotechnology businesses' increasing R&D expenditures. As new products are introduced and technology continues to progress, the NGS sample preparation market is predicted to grow steadily in the upcoming years.

Market Drivers:

  • Advancement in genome research is anticipated to boost the NGS sample preparation market.

Advancements in genomic research are a key driver of the NGS sample preparation market. As genomic research progresses, the demand for NGS technologies increases, spurring the need for efficient and reliable sample preparation methods. Researchers and clinicians rely on NGS to uncover insights into genetic variation, disease mechanisms, and personalized medicine applications. Consequently, there is a growing emphasis on developing innovative sample preparation solutions that can handle diverse sample types, improve workflow efficiency, and ensure high-quality sequencing data.

These advancements propel market growth by meeting the evolving needs of genomic research across various fields and applications. For example, Agilent successfully acquired Resolution Bioscience in 2021. Resolution Bioscience is a pioneer in the creation and marketing of precision cancer solutions based on next-generation sequencing. Agilent's capabilities in NGS-based cancer diagnostics were enhanced and augmented by Resolution Bioscience, which also gave Agilent access to cutting-edge technology to better meet the demands of the rapidly expanding precision medicine market.

  • Rising demand for personalized medicine is expected to boost the NGS sample preparation market.

The rising demand for personalized medicine is a significant driver of the genome research market. Personalized medicine tailor treatment strategies to individual patients based on their genetic makeup, enabling more precise and effective healthcare interventions. This paradigm shift has led to increased investment in genomic research to uncover genetic markers associated with diseases, treatment response, and drug efficacy.

Furthermore, advancements in sequencing technologies have made genomic analysis more accessible, allowing clinicians to integrate genetic information into patient care decisions. As a result, there is growing momentum in genome research, driven by the imperative to realize the full potential of personalized medicine in improving patient outcomes. For instance, Illumina Inc. introduced its next-generation NovaSeq X systems in September 2022. These systems can produce 2.5 times as many whole genomes annually as previous sequencers or over 20,000 genomes annually.

  • Technological advancements are anticipated to boost the NGS sample preparation market.

Technological advancements play a pivotal role in driving the NGS sample preparation market. Continuous innovation in sample preparation methods and instrumentation has led to the development of more efficient, accurate, and high-throughput workflows. Automation, miniaturization, and integration of multiple steps have streamlined sample preparation, reducing turnaround times and costs. Moreover, advancements in sequencing platforms, such as increased throughput and improved read lengths, necessitate corresponding improvements in sample preparation to maximize the potential of NGS technologies.

These technological strides not only enhance the performance of NGS assays but also expand the application areas, driving market growth and adoption across diverse fields. With the introduction of QIAseq Targeted DNA Pro Panels and the QIAseq UPXome RNA Library Kit in August 2022, QIAGEN broadened the scope of its next-generation sequencing (NGS) offering. In terms of sample preparation for identifying their nucleic acid sequences, both have established new benchmarks. 

Asia Pacific region is expected to grow significantly.

The Asia Pacific region is experiencing significant growth in the NGS sample preparation market. Factors driving this expansion include the increasing adoption of NGS technologies in research, clinical diagnostics, and agriculture. Rapid economic development, expanding healthcare infrastructure, and rising investments in genomics research contribute to market growth. Additionally, supportive government initiatives and collaborations with international organizations drive innovation and market penetration.

Furthermore, the region's large population base and high disease burden create substantial demand for advanced genomic technologies, propelling the NGS sample preparation market forward in Asia Pacific. For example, Bio-Rad Laboratories, Inc. and Seegene, Inc., a pioneer in multiplex molecular diagnostics and life science research worldwide, announced a collaboration in June 2021 for the clinical development and commercialization of products related to infectious diseases. This has provided the business with a chance to expand its product line and sales internationally.

 Market Restraints:

  • Standardization and quality control can constrain the market for NGS sample preparation.

The requirement for standardization and quality control is a significant obstacle in the market for NGS sample preparation. The growing need for NGS technology in a variety of applications makes it essential to establish standardized and repeatable procedures for sample preparation. Inconsistencies in results might be caused by variations in sequencing platforms, library preparation methods, and sample quality, which makes it more difficult to interpret data and perform downstream studies. To assure dependable and accurate NGS results, addressing this difficulty calls for the creation of standardized methods, strong quality control mechanisms, and industry-wide norms.

Market Development:

  • July 2023- The QIAseq Normalizer Kits, which provide researchers with an easy, quick, and affordable way to pool various DNA libraries for the highest-quality results from NGS runs, were recently introduced by QIAGEN By eliminating the need to quantify DNA libraries using time-consuming and costly processes, the QIAseq Normalizer Kit speeds up the process of equalizing DNA concentrations across NGS libraries, also known as normalization, from several hours to 30 minutes. It is safe to use without chemicals, has an automated process for the parallel normalization of 96 samples, and operates at high throughput.
  • April 2023- Illumina Inc., a global leader in DNA sequencing and array-based technologies, today announced it has already exceeded more than 200 orders for its revolutionary NovaSeq X sequencing system in the first quarter of 2023. The orders represent a diverse customer base spanning research and clinical customer segments in nearly 30 countries, across five continents, all seeking to add NovaSeq X – the fastest, most powerful, most sustainable high-throughput sequencer available.

Market Segmentation

  • By Product:
    • Reagent and Consumables
    • Workstations
  • By Application:
    • Diagnostics
    • Drug discovery
    • Others
  • By End-user:
    • Hospitals and clinics
    • Pharmaceutical and Biotechnology Companies
    • Academic & Research Institutes
    • Others
  • By Geography:
    • North America
      • United States
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • United Kingdom
      • Germany
      • France
      • Italy
      • Spain
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • UAE
      • Others
    • Asia Pacific
      • Japan
      • China
      • India
      • South Korea
      • Taiwan
      • Thailand
      • Indonesia
      • Others


1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

1.8. Key Benefits for the Stakeholder


2.1. Research Design

2.2. Research Processes


3.1. Key Findings

3.2. Analyst View


4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

4.5. Analyst View


5.1. Introduction

5.2. Reagent and Consumables

5.2.1. Market Trends and Opportunities

5.2.2. Growth Prospects

5.3. Workstations 

5.3.1. Market Trends and Opportunities

5.3.2. Growth Prospects


6.1. Introduction

6.2. Diagnostics

6.2.1. Market Trends and Opportunities

6.2.2. Growth Prospects

6.3. Drug Discovery

6.3.1. Market Trends and Opportunities

6.3.2. Growth Prospects

6.4. Others

6.4.1. Market Trends and Opportunities

6.4.2. Growth Prospects


7.1. Introduction

7.2. Hospitals and Clinics

7.2.1. Market Trends and Opportunities

7.2.2. Growth Prospects

7.3. Pharmaceutical and Biotechnology Companies

7.3.1. Market Trends and Opportunities

7.3.2. Growth Prospects

7.4. Academic & Research Institutes

7.4.1. Market Trends and Opportunities

7.4.2. Growth Prospects

7.5. Others

7.5.1. Market Trends and Opportunities

7.5.2. Growth Prospects


8.1. Introduction

8.2. North America

8.2.1. By Product

8.2.2. By Application

8.2.3. By End-User

8.2.4. By Country United States Market Trends and Opportunities Growth Prospects Canada Market Trends and Opportunities Growth Prospects Mexico Market Trends and Opportunities Growth Prospects

8.3. South America

8.3.1. By Product

8.3.2. By Application

8.3.3. By End-User

8.3.4. By Country Brazil Market Trends and Opportunities Growth Prospects Argentina Market Trends and Opportunities Growth Prospects Others Market Trends and Opportunities Growth Prospects

8.4. Europe

8.4.1. By Product

8.4.2. By Application

8.4.3. By End-User

8.4.4. By Country United Kingdom Market Trends and Opportunities Growth Prospects Germany Market Trends and Opportunities Growth Prospects France Market Trends and Opportunities Growth Prospects Italy Market Trends and Opportunities Growth Prospects Spain Market Trends and Opportunities Growth Prospects Others Market Trends and Opportunities Growth Prospects

8.5. Middle East and Africa

8.5.1. By Product

8.5.2. By Application

8.5.3. By End-User

8.5.4. By Country Saudi Arabia Market Trends and Opportunities Growth Prospects UAE Market Trends and Opportunities Growth Prospects Others Market Trends and Opportunities Growth Prospects

8.6. Asia Pacific

8.6.1. By Product

8.6.2. By Application

8.6.3. By End-User

8.6.4. By Country Japan Market Trends and Opportunities Growth Prospects China Market Trends and Opportunities Growth Prospects India Market Trends and Opportunities Growth Prospects South Korea Market Trends and Opportunities Growth Prospects Taiwan Market Trends and Opportunities Growth Prospects Thailand Market Trends and Opportunities Growth Prospects Indonesia Market Trends and Opportunities Growth Prospects Others Market Trends and Opportunities Growth Prospects


9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard


10.1. Illumina, Inc.

10.2. Agilent Technologies, Inc.

10.3. Bio-Rad Laboratories, Inc.

10.4. Thermo Fisher Scientific Inc.

10.5. Qiagen N.V.

10.6. PerkinElmer Inc.

10.7. F. Hoffmann-La Roche Ltd

10.8. BGI Genomics


10.10. Danaher Corporation (Beckman Coulter)

Illumina, Inc.

Agilent Technologies, Inc.

Bio-Rad Laboratories, Inc.

Thermo Fisher Scientific Inc.

Qiagen N.V.

PerkinElmer Inc.

F. Hoffmann-La Roche Ltd

BGI Genomics


Danaher Corporation (Beckman Coulter)